一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Tazemetostat；Placebo oral tablet；Lenalidomide；Rituximab，当前状态为研究进行中，已停止招募。登记地点显示中国福州、厦门、贵阳、浙江省等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tazemetostat；Placebo oral tablet；Lenalidomide；Rituximab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fujian Medical University Union Hospital · 福州
- The First Affiliated Hospital of Xiamen University · 厦门
- The Affiliated Hospital of Guizhou Medical University · 贵阳
- The Second Affiliated Hospital Zhejiang University School of Medicine · 浙江省
- The Fourth Hospital of Hebei Medical University · 石家庄
- Henan Provincial People's Hospital · 郑州
- Henan Cancer Hospital · 郑州
- Hunan Cancer Hospital · 长沙
- The First Bethune Hospital of Jilin University · 长春
- The Affiliated Hospital of Qingdao University · 青岛
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine · 上海
- Shanxi Bethune Hospital · 太原
- Peking University Third Hospital · 北京
- The First Affiliated Hospital Zhejiang University School of Medicine · 杭州
- Tongji Hospital of Tongji Medical College of HUST · 杭州
- Jiangxi Cancer Hospital · 南昌
- Shandong Cancer Hospital · 山东省
- Tongji Hospital of Tongji University · 上海
- Sichuan Provincial People's Hospital · 四川省
- Tianjin Medical University Cancer Institute & Hospital · 天津
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol.
- 2. Males or females are ≥18 years of age, or per country adult legal age regulations, at the time of providing voluntary written informed consent.
- 3. Life expectancy ≥3 months before enrollment.
- 4. Meet requirement for hepatitis and human immunodeficiency virus (HIV) infection as follows
- Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection Note: Participants whose HBV infection status could not be determined by serologic test results have to be negative for HBV-DNA by PCR to be eligible for study participation. Participants seropositive for HBV with undetectable HBV DNA by PCR are permitted with appropriate antiviral prophylaxis.
- Negative test results for hepatitis C virus (HCV) Note: Participants who are positive for HCV antibody must be negative for HCV RNA by PCR to be eligible for study participation
- If HIV positive, HIV infection is controlled. Based on Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections
- Guidance for Industry (https://www.fda.gov/media/121319/download), patients with HIV should be considered eligible if they have CD4+ T-cell counts ≥ 350 cells/uL and in general, if they have not had an opportunistic infection within the past 12 months. Other exclusion criteria should be considered regarding the drug-drug interaction if antiviral drugs are used. Therefore, in case of controlled HIV infection, since antiviral drugs are used, trial patients should be on established ART for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrolment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04224493；登记信息更新于 2026-10-05；本站同步于 2026-10-08。